Premium Essay

Drug Patents

In: Business and Management

Submitted By pszczolapi
Words 299
Pages 2
Drug patents

The role of the patent system in promoting pharmaceutical innovation is widely seen as a tremendous success story. This view overlooks a serious shortcoming in the drug patent system: the standards by which drugs are deemed unpatentable under the novelty and non-obviousness requirement bear little relationship to the social value of those drugs or the need for a patent to motivate their development. If the idea for a drug is not novel or is obvious, perhaps because it was disclosed in an earlier publication or made to look obvious by recent scientific advances, then it cannot be patented. Yet the mere idea for a drug alone is generally of little value to the public. Without clinical trials proving the drug's safety and efficacy, a prerequisite for FDA approval and acceptance by the medical community, it is unlikely to benefit the public. Given the immense investment needed to fund clinical trials on drugs, and the ability of generic manufacturers to rely on those tests to secure regulatory approval for their own products, pharmaceutical companies are rarely willing to develop a drug without patent protection. The novelty and non-obviousness requirements make no concession for the development costs of inventions, and thus withhold patents from drugs that are unlikely to reach the public without that protection. This gap in the patent system for drugs has created a pervasive problem in the pharmaceutical industry, causing firms to regularly screen through their drugs in R&D and discard ones with weak patent protection. The potential harm to the public from the loss of these drugs is likely significant. Congress can easily avoid this problem by ensuring that the successful completion of the FDA's rigorous clinical trial process is rewarded with a lengthy exclusivity period enforced by the...

Similar Documents

Premium Essay

Employee Empowerment

...Patent for Imatinib had already been obtained by Novartis on April 2, 1993. Novartis claimed that this invention involved two aspects: 1. Selecting an example from the Zimmermann patent and then choosing methane sulphonic acid addition salt of the free base Imatinib, which was called Imatinib Mesylate. 2. Making the invention suitable for oral consumption and use. This led to the formation of the beta-crystalline form of the above drug. Opponents of the patent filed by Novartis charged saying that the first invention had merely been picked up from the Zimmermann patent and couldn’t actually be classified as an invention and that the claims by Novartis were false[3]. Hence, the SC had to first determine the veracity of the claims made by the company. For this, the bench studied the relevant clauses of the Zimmermann patent in detail. It was found that Novartis had indeed disclosed both Imatinib and Imatinib Mesylate in the Zimmermann patent and had also directed Natco Pharma to stop selling their drug Veenat, in Europe [4]. Veenat involved the use of Imatinib Mesylate and was infringing upon their European equivalent of the Zimmermann patent[4]. Hence, the court declared that only the second invention of the formation of the beta-crystalline form could be actually termed as an “invention”. Once this was done, Novartis had to pass the bar of calling its invention a “patent”. Section 3(d) of the Act clearly states that discovery of a new form of a known substance......

Words: 1215 - Pages: 5

Free Essay

Cipla History

...was registered as a public limited company in Mumbai. Khwaja Abdul Hamied, the founder of Cipla (Chemical, Industrial & Pharmaceutical Laboratories) was gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. * 1941–As the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort and helped British with drugs during World War II to create goodwill so that after war we India can request for freedom * 1952– Sets up first research division for attaining self–sufficiency in technological development.  * 1960– Starts operations at second plant at Vikhroli, Mumbai, producing fine chemicals with special emphasis on natural products.  * 1960- Cipla began manufacturing a new, patented drug, propranolol, and when the drug's patent holder, ICI, protested to the Indian government, the CEO of Cipla successfully lobbied the government of Indira Gandhi to change India's patent laws to eliminate patents that directly covered drugs, and instead to allow only patents that covered methods to make drugs. This change made propranolol and other patented drugs, generic and led to criticism of both India's patent laws and Cipla. India reinstated patents on drugs in 2005 * 1968– Cipla manufactures ampicillin for the first time in the country.  * 1972–Starts Agricultural Research Division at Bangalore, for scientific cultivation of......

Words: 875 - Pages: 4

Premium Essay

Right of Oatent

...Rights of patentees (1) Subject to the other provisions contained in this Act, a patent granted before the commencement of this Act, shall confer on the patentee the exclusive right by himself, his agents or licensees to make, use, exercise, sell or distribute the invention in India. (2) Subject to the other provisions contained in this Act and the conditions specified in section 47, a patent granted after the commencement of this Act shall confer upon the patentee - where the patent is for an article or substance, the exclusive right by himself, his agents or licensees to make, use, exercise, sell or distribute such article or substance in India; Where a patent is for a method or process of manufacturing an article or substance, the exclusive right by himself, his agents or licensees to use or exercise the method or process in India. Term of Patent (1) Subject to the provisions of this Act, the term of every patent granted under this Act shall - in respect of an invention claiming the method or process of manufacture of a substance, where the substance is intended for use, or is capable of being used, as food or as a medicine or drug, be five years from the date of sealing of the patent, or seven years from the date of the patent whichever period is shorter; and in respect of any other invention, be fourteen years from the date of the patent. (2) A patent shall cease to have effect notwithstanding anything therein or in this Act on the expiration of the period......

Words: 715 - Pages: 3

Premium Essay

Novartis Case Study Analysis

...granted patent in both the US and Europe. Beginning with Imatinab in its base form. 4. Novartis claims to have developed Beta Crystalline form of Imatinab in a two-stage process and a direct process, with obtaining Imatinab Mesylate in amorphous form as an output in the stage one of the two-stage process. 5. An application was filed for the patent of the beta crystalline form of Imatinab Mesylate in India claiming that the newly invented form had more beneficial flow properties, thermodynamic stability and a lower hygroscopicity than the original Imatinab. 6. Further, they claimed it has better storage properties and that it was easier to process than the Imatinab in basic form. 7. However it was also claimed in the application for patent that all the inhibitory and pharmacological effects of the beta crystalline form of Imatinab Mesylate were also found in the base form of the compound. Novartis: Law Points and Development of the Case 1. When the application was filed for patent in the year 1995,the patent laws in India were under transition phase and as a result the application held in a dormant mode. 2. Later in March 2002, the applicant makes another application for Exclusive Marketing Rights (EMR) of the product under the section 24A of Indian Patent Acts 1970, which now stands deleted following the amendments to the Indian Patent Act, and in the due course, the EMR for the product was granted to the applicant. 3. However during the period of EMR, the drugs......

Words: 1511 - Pages: 7

Premium Essay

Merck & Company: Evaluating a Drug Licensing Opportunity

...been able to achieve substantial returns to capital given the large costs and lengthy time to develop drugs? II. How much should they pay? III. What is the expected value of the licensing arrangement to LAB? IV. How would our analysis change if the costs of launching Davanrik for weight loss were $225 million instead of $100 million? In our analysis we will build a decision tree that shows the cash flows and probabilities at all stages of the FDA approval process. We will assume a royalty fee of 5% on the cash flows that Merck receives from Davanrik after successful launch. Analysis Merck is in the business of developing compounds for pharmaceutical compounds. The required research and development efforts preceding the launch of a successful blockbuster drug is extensive and lengthy process and is therefore a very expensive one. Nevertheless, Merck has proven perfectly capable to achieve high returns on capital. This is a result of numerous factors. First of all, Merck has been able to generate tremendous amounts of sales. Since 1995, Merck has launched 15 new products, resulting in 1999 sales of $32.7 billion, which includes $15.2 billion in pharmaceutical benefit management services (PBM) sales. Some products were developed through joint ventures, allowing for a division of costs but also future revenues. Furthermore, these new products are protected by law under patents, which give Merck the exclusive rights to the production and sales. Since Merck is then the......

Words: 581 - Pages: 3

Free Essay

Trade Secrets

...trade secrets. Unlike patents which require the secret to be inventive or non-obvious, things such as customer lists, equations, and compilation of data (which aren't eligible for copyright or patent protection) can be protected through a trade secret. Granted, though, that the company assumes the costs associated with protecting the said secret. Whereas patents expire after 20 years, and all the designs/specifications are consequently available to the public domain, trade secrets can be protected for longer; this depends on the secret holders ability to adequately establish a framework to maintain secrecy and thereby protect the intellectual property. In the cases of Coca-Cola and KFC, the process of keeping trade secrets has benefited them greatly. Granted, though, they also use a symbiotic or symphonic combination of patents, trademarks, and copyrights to protect their overall product; no competitor has been able to completely replicate their products because the processes making the syrup (for Coca-Cola) or the method of mixing the spices (for KFC) has been a closely guarded trade secret. Had these companies patented these processes, they would have received initial protection for 20 years from anyone replicating it, but would have had these processes disclosed to the public after that. Whereas these companies have been in existence for a longer time, a patent for the processes wouldn't have been in their best long-term interest. Whereas patents (while valid)......

Words: 618 - Pages: 3

Free Essay

Macs101

...Critical Review 1 In recent years, patents, copyrights and trademarks have become more and more prevalent. Nowadays, people are trying and in some instances succeeding in trademarking things such as human genes, scents, and even phrases such as Donald Trump’s “You’re Fired”. Kembrew Mcleod in his article titled, “Freedom of Expression: Overzealous Copyright Bozos and Other Enemies of Creativity” analyzes the effects that patents and copyrights have on our society today. Mcleod uses numerous examples and anecdotes to emphasize his main point that patents and copyrights are getting out of hand and restricting our freedom of expression. Mcleod presents a very convincing argument in this article and does a great job explaining how trademark holders are going to the extreme to protect their property. Mcleod believes that our freedom of expression is being eroded because of the expansion of the patent law in the last quarter of the century. As a result, many things are becoming privatized. In the article, Mcleod discusses an incident regarding a man named Moore, who had his spleen removed to treat his leukemia. The doctor that did the procedure patented a cell line taken from his organ without Moore’s consent. The doctor went on to develop a drug from the patent and Moore did not reap any of the benefits of the success of the drug because of the doctor’s patent. This example proves that what some people are patenting these days is getting out of hand. In the article,......

Words: 721 - Pages: 3

Premium Essay

Eli Lilly

...as opposed to low costs in India and new regulations that opened Indian market to foreign investments (up to 51%) created tempting conditions to enter one of the emerging huge markets of the world. Alliance with Ranbaxy was a smart strategy for Eli Lilly to establish its presence in India. Ranbaxy was the second largest manufacturing company of bulk drugs and generics with domestic market share of 15% in India with established distribution network and the second largest exporter to different countries, including Russia (which Eli Lilly was attempting to reach), with capital cost 50-75% lower than those of comparable US plant and R&D expenses of 2-5% of sales. Besides, Ranbaxy developed its own process for Eli Lilly's patented drug Cefaclor. Since Eli Lilly's product patent for Cefaclor expired in 1992 and the firm was expecting to protect its monopoly with process patents which were due to expire only in 1994, this gave great scope for a mutually advantageous agreement between the two companies. There was also possibility to conduct cheap clinical trials in India. Although the joint venture ran into problems because of weak patent laws in the country, which prevented the American partner from sharing its research expertise, Eli Lilly obviously, realized the benefits of an arrangement with Ranbaxy in sourcing low-cost basic research from India. Question 2: Evaluate the three successive IJV leaders. Identify the...

Words: 960 - Pages: 4

Free Essay

Risk Arising in Tangible and Intellectual Property in Pharmaceutical Industry.

...development is main reasons for its success. Intellectual property protection has a goal to insure return on investment and future profits. Discovering and testing a new drug is a process that requires approval from regulatory agencies in the United States and Europe. This process might cost millions of dollars per new product. After such a large investment has been made, next step is to obtain approvals in other nations. This approval is necessary so that new product can be sell as widely as possible. The main risk that pharmaceutical industry is facing is imitation. Once a product have been developed to be safe and effective risk is that another firm might enter the market with same or similar products. It is much cheaper and faster to invest in manufacturing process and developing existing and start competing with the pioneering firm with lower prices. If such imitation were widespread and rapid, pioneer company might not have ROI( return on investment) Inequality between drug finding and imitation costs, led pharmaceutical manufacturers to stress on the importance of the patent system. Well developed patent system can allow company to have 20 years of exclusive rights to their invention, in order for them to recover initial investment . Patent protection is one of the main reasons for...

Words: 719 - Pages: 3

Premium Essay

International Legal and Ethical Issues

...International Legal and Ethical Issues Contemporary Business Law-LAW/421 Dina Centifanti Gledhill May 28, 2012 International trade is important and beneficial to business. However international trade must be guided with a safeguard of interests, specific business contract, defined law, forum of dispute settlement, and understanding of contract clauses. “A working knowledge of international law helps business owners and managers with global interests reduce risk and increase profits” (Melvin, 2011, P. 631). This enlightenment will address the international legal and ethical issues involved in international business transactions and compare such to domestic business operations. Resolving legal disputes Business internationally, enviably creates change in legislation, interest conflict, and rise of ethical dilemmas. When international business arises, business owners, and management must use precaution to avoid ethical, legal, and cultural issues. Business must prepare for the unexpected to ensure success. Often conducting foreign business requires the parties to set standard law, determine how to settle disputes, and define contract clause to determine the correct business decision applicable through contracts. Foreign businesses commonly use contracts for the international sale of goods as standard law. “Contracts for the international sale of goods was created by the U.N. Commission on International Trade Law to establish uniform rules for drafting certain......

Words: 652 - Pages: 3

Premium Essay

Novartis Judgement Report

...Novartis V. Union of India & Others – A Landmark Judgement on Indian Patent Law & Pharmaceutical Industry: A Report The Supreme Court judement on the Novartis v. Union of India & Others is a landmark decision on the issue of pharmaceutical patent in India. The decision taken after a seven year long litigation fought by pharmaceutical major Novartis is based on a case pertaining to grant of Indian patent on a compound called Imatinib Mesylate in Beta Crystalline Form (referred as Imatinib hereinafter as convenience of brevity). The Supreme Court decided that Imatinib, the substance for which Novartis sought patent does not qualify the test of invention as laid down in section 2(1)(j), section 2(1)(ja) and the test of efficacy under section 3(d) of the Indian Patent Act, 1970. The decision generated widespread discussion and debate on affordability of life saving drugs in India for public good and impact on R&D for further innovation in pharmaceutical industry. The report covers following contents. 1. Background of the Novartis Case ❖ Fact of the case ❖ Underlying legal provisions 2. Overview of patent law in India with special focus on pharmaceutical industry 3. Supreme Court Decision in Novartis Case 4. Impact of the Supreme Court Judgement ❖ On affordability of life saving drugs ❖ On innovation for future improvement and development ❖ Overall impact on pharmaceutical......

Words: 2339 - Pages: 10

Premium Essay

Dr Narendran's Dilemma

...AHMEDABAD For requirements of the course Written Analysis and Communication - I (2011-13) Dr. Narendran’s Dilemma Submitted to: Name of instructor: Prof Asha Kaul Name of Academic Associate: Shilpa Sawant Submitted by: S.G.Shrinivas Section A Date of Submission: 2nd July 2011 LETTER OF TRANSMITTAL From S G Shrinivas, Student, WIMWI To Dr. Narendran Director, Indian Medicine (Siddha) College Chennai Respected Sir, Subject: Dr. Ramkumar’s request to IMC to apply for a patent This is with reference to the earlier interactions between us regarding Dr. Ramkumar’s research. Please find along with my report on the same, consisting of an analysis of the situation, the various options available to you and my evaluation of the options. My recommendation would be to go ahead with the patent, by selling it to a third party for a one-time licensing fee. Regards S G Shrinivas EXECUTIVE SUMMARY Dr. Ramkumar wants to apply for a patent for his research on a cost-effective Siddha product for coronary atherosclerosis. A decision, whether to go ahead with the request, will have to be made, as this could have long standing implications for both Siddha and the institute. Among the options available for patenting the product - One-time licensing fee or leaving the manufacturing to a pharmaceutical unit or selling it on a royalty basis - the first option seems to be the most beneficial, on the basis of evaluation on the IMC Mandate, revenues......

Words: 1598 - Pages: 7

Premium Essay

Mba Hr

...Monday, April 21, 2008 Roche vs CIPLA: The Rhetoric of Patent Busting Roche, a multinational pharma company and CIPLA, a generic manufacturer from India. CIPLA brazenly defied Roche's patent over an anticancer drug, Tarceva and went ahead and introduced a generic version at 1/3rd the price. It claimed that the patent ought not have been granted in the first place. CIPLA's counsel, Arun Jaitley argued very persuasively in court that Roche's drug did not meet the requirements of section 3(d), a unique section introduced into India's patent regime in 2005 to prevent a phenomenon widely known as "evergreening". Under section 3(d), derivatives of existing pharmaceutical substances would not merit patent protection, unless such derivative was more "efficacious" than the earlier existing pharma substance. The section was challenged by Novartis as being violative of TRIPS and of the Indian constitution CIPLA also stressed that since the price differential between the patented drug and the generic version sold by CIPLA was extremely high, "public interest" demanded that no injunction be granted in favour of Roche. In a remarkably sophisticated and well researched judgment, Justice S Ravindra Bhat of the Delhi High Court ruled in favour of CIPLA. The matter is now under appeal. Unless Roche is able to demonstrate empirically that CIPLA's lower prices for Tarceva (the lung cancer drug in issue) does not really translate to increased access to poor patients, it is difficult...

Words: 7301 - Pages: 30

Premium Essay

Mba Essay

...A “Calibrated Approach”: Pharmaceutical FDI and the Evolution of Indian Patent Law Web version: August 2007 Authors: Katherine Connor Linton and Nicholas Corrado1 Abstract India has charted its own intellectual property (IP) path over the last 35 years, attempting to foster the growth of a domestic pharmaceutical industry and access to medicine while, more recently, also addressing the requirements of the international IP regime. Multinational companies (MNCs) have responded to India’s movement towards compliance with the W TO intellectual property agreement, TRIPS, by increasing the quantity and quality of foreign direct investment (FDI) in the areas of pharmaceutical research and development (R&D) and manufacturing. By contrast, MNCs have adopted a more cautious attitude toward the patenting and commercialization of new pharmaceutical products in India, waiting to see how Indian courts and patent offices interpret the new laws, and awaiting the enactment of longdebated data protection legislation. The ultimate success of the Indian “calibrated approach” to fostering the domestic industry and access to medicine while also addressing international IP requirements remains to be seen. 1 Katherine Connor Linton (katherine.linton@usitc.gov) is the International Trade Analyst for Intellectual Property and Nicholas Corrado was a law student intern in the Office of Industries of the U.S. International Trade Commission (USITC). The views expressed are those of Ms. Linton......

Words: 6873 - Pages: 28

Premium Essay

Reasons for Small Business Failure in Tanzania

...MARIAM LIANA Introduction This paper explores the impact of pharmaceutical patent laws on Anti-AIDS drug, substantial controversy which has been generated around the globe on ethical grounds. Pharmaceutical patents on Anti-AIDS drug availability in the third world countries, focusing on an ethics of the Trade Related Aspects of Intellectual Property Rights (TRIPs) Agreement. It highlights the value of essential drugs and generic production in developing countries, using India, Cipla as a case study. It also explores global ways to deal with unethical grounds to TRIPs. History of Cipla, Indian Pharmaceutical Company Cipla is one of the world's largest producers of generic medicines.Cipla is one of India's top five pharmaceutical manufacturers. Although Cipla's primary market is India, the company sells its products worldwide. Cipla's lines of more than 400 drugs include anti-asthmatic, anti-cancer, anti-inflammatory, anti-depressant and anti-AIDS medications. Over the years, the company has developed strong research and marketing capabilities. In recent times, Cipla has attracted considerable media attention because of its efforts to offer AIDS drugs globally at very low prices. But in its quest to capture this market, Cipla faces the might of global multinational corporations, who are doing all they can to protect and enforce their patent rights. The case deals with all these issues in detail. World Trade Organization’s (WTO) The World......

Words: 2840 - Pages: 12